Trials / Unknown
UnknownNCT03755466
Examination of Efficacy and Safety of Baricitinib in RA Patients
Efficacy and Safety of Baricitinib in Rheumatoid Arthritis Patients Compared With Those Treated by Biologics or Tofacitinib
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Shinshu University · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients: 1. Baricitinib treatment for 12 months 2. Biologics treatment for 12 months 3. Tofacitinib treatment for 12 months
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | "Baricitinib", "olumiant®" | To examine the effects of baricitinib in RA patients |
| DRUG | "Biologics" | To examine the effects of biologics in RA patients |
| DRUG | Tofacitinib 5 MG [Xeljanz] | To examine the effects of tofacitinib in RA patients |
Timeline
- Start date
- 2018-11-21
- Primary completion
- 2023-11-20
- Completion
- 2025-11-20
- First posted
- 2018-11-28
- Last updated
- 2021-09-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03755466. Inclusion in this directory is not an endorsement.